在前列腺癌中SGLT2抑制剂启动和PSA反应的关联
Etan R Aber1, Michael A Carducci2, Channing J Paller2
1Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
The Prostate
|December 22, 2024
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂显示为前列腺癌的非割疗法有前途,一些患者获得前列腺特异性抗原 (PSA) 反应. 需要进一步的研究来证实这些发现.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
背景情况:
- 晚期前列腺癌需要非割疗法来保持生活质量和心血管健康.
- SGLT2 抑制剂正在作为一种新的治疗选择进行研究.
- 目前的治疗环境缺乏足够的非激素治疗方案来治疗前列腺癌.
研究的目的:
- 研究SGLT2抑制剂作为前列腺癌患者非割治疗的疗效.
- 评估SGLT2抑制剂对前列腺特异性抗原 (PSA) 水平的影响.
- 在患有局部或生化复发前列腺癌的患者中评估SGLT2抑制剂.
主要方法:
- 对接受SGLT2抑制剂的9名前列腺癌患者的回顾性分析.
- 患者患有局部或生化复发性疾病.
- 排除并发的雄激素剥夺疗法;主要终点是PSA50反应率.
主要成果:
- 在9名患者中,有2名患者 (22.2%) 获得了PSA50应答.
- 9名患者中有4名 (44.4%) 显示出任何PSA反应.
- 患者的中位数年龄为63岁,44.4%是黑人;中位数PSA为3.7.
结论:
- SGLT2 抑制剂在局部或生化复发前列腺癌患者中显示出诱导PSA反应的潜力.
- 这些初步发现支持了未来临床试验的必要性.
- 对于精选的前列腺癌患者来说,SGLT2抑制剂可能是一个可行的非割治疗策略.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
01:23Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167